BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 20639906)

  • 1. The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo.
    Merdzhanova G; Gout S; Keramidas M; Edmond V; Coll JL; Brambilla C; Brambilla E; Gazzeri S; Eymin B
    Oncogene; 2010 Sep; 29(39):5392-403. PubMed ID: 20639906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SC35.
    Merdzhanova G; Edmond V; De Seranno S; Van den Broeck A; Corcos L; Brambilla C; Brambilla E; Gazzeri S; Eymin B
    Cell Death Differ; 2008 Dec; 15(12):1815-23. PubMed ID: 18806759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma.
    Pritchard-Jones RO; Dunn DB; Qiu Y; Varey AH; Orlando A; Rigby H; Harper SJ; Bates DO
    Br J Cancer; 2007 Jul; 97(2):223-30. PubMed ID: 17595666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis.
    Nowak DG; Amin EM; Rennel ES; Hoareau-Aveilla C; Gammons M; Damodoran G; Hagiwara M; Harper SJ; Woolard J; Ladomery MR; Bates DO
    J Biol Chem; 2010 Feb; 285(8):5532-40. PubMed ID: 19906640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Balance of pro- versus anti-angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth.
    Peiris-Pagès M; Harper SJ; Bates DO; Ramani P
    J Pathol; 2010 Oct; 222(2):138-47. PubMed ID: 20662003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis.
    Manetti M; Guiducci S; Romano E; Ceccarelli C; Bellando-Randone S; Conforti ML; Ibba-Manneschi L; Matucci-Cerinic M
    Circ Res; 2011 Jul; 109(3):e14-26. PubMed ID: 21636803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor.
    Perrin RM; Konopatskaya O; Qiu Y; Harper S; Bates DO; Churchill AJ
    Diabetologia; 2005 Nov; 48(11):2422-7. PubMed ID: 16193288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VEGF₁₂₁b and VEGF₁₆₅b are weakly angiogenic isoforms of VEGF-A.
    Catena R; Larzabal L; Larrayoz M; Molina E; Hermida J; Agorreta J; Montes R; Pio R; Montuenga LM; Calvo A
    Mol Cancer; 2010 Dec; 9():320. PubMed ID: 21194429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors.
    Nowak DG; Woolard J; Amin EM; Konopatskaya O; Saleem MA; Churchill AJ; Ladomery MR; Harper SJ; Bates DO
    J Cell Sci; 2008 Oct; 121(Pt 20):3487-95. PubMed ID: 18843117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anti-angiogenic isoforms of VEGF in health and disease.
    Qiu Y; Hoareau-Aveilla C; Oltean S; Harper SJ; Bates DO
    Biochem Soc Trans; 2009 Dec; 37(Pt 6):1207-13. PubMed ID: 19909248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p73 Isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors: VEGF165b downregulation as a marker of poor prognosis.
    Díaz R; Peña C; Silva J; Lorenzo Y; García V; García JM; Sánchez A; Espinosa P; Yuste R; Bonilla F; Domínguez G
    Int J Cancer; 2008 Sep; 123(5):1060-7. PubMed ID: 18546269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of VEGF-dependent tumour micro-environment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice.
    Coltrini D; Ronca R; Belleri M; Zardi L; Indraccolo S; Scarlato V; Giavazzi R; Presta M
    J Pathol; 2009 Dec; 219(4):455-62. PubMed ID: 19824060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm.
    Ladomery MR; Harper SJ; Bates DO
    Cancer Lett; 2007 May; 249(2):133-42. PubMed ID: 17027147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Alternative splicing of vascular endothelial growth factor A and ocular neovascularization].
    Fan SJ; He SZ
    Zhonghua Yan Ke Za Zhi; 2011 Apr; 47(4):373-7. PubMed ID: 21612688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antitumor and anti-angiogenic effects of manumycin on human hepatocellular carcinoma HepG2 xenografts in nude mice].
    Zhou JM; Zhu XF; Liu ZC; Fu LW; Yang XP; Liang YJ; Pan QC
    Ai Zheng; 2005 Aug; 24(8):935-9. PubMed ID: 16086869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance.
    Hamdollah Zadeh MA; Amin EM; Hoareau-Aveilla C; Domingo E; Symonds KE; Ye X; Heesom KJ; Salmon A; D'Silva O; Betteridge KB; Williams AC; Kerr DJ; Salmon AH; Oltean S; Midgley RS; Ladomery MR; Harper SJ; Varey AH; Bates DO
    Mol Oncol; 2015 Jan; 9(1):167-78. PubMed ID: 25224594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF.
    Qin G; Kishore R; Dolan CM; Silver M; Wecker A; Luedemann CN; Thorne T; Hanley A; Curry C; Heyd L; Dinesh D; Kearney M; Martelli F; Murayama T; Goukassian DA; Zhu Y; Losordo DW
    Proc Natl Acad Sci U S A; 2006 Jul; 103(29):11015-20. PubMed ID: 16835303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VEGF Splicing and the Role of VEGF Splice Variants: From Physiological-Pathological Conditions to Specific Pre-mRNA Splicing.
    Guyot M; Pagès G
    Methods Mol Biol; 2015; 1332():3-23. PubMed ID: 26285742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.
    Mavrou A; Brakspear K; Hamdollah-Zadeh M; Damodaran G; Babaei-Jadidi R; Oxley J; Gillatt DA; Ladomery MR; Harper SJ; Bates DO; Oltean S
    Oncogene; 2015 Aug; 34(33):4311-9. PubMed ID: 25381816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered VEGF Splicing Isoform Balance in Tumor Endothelium Involves Activation of Splicing Factors Srpk1 and Srsf1 by the Wilms' Tumor Suppressor Wt1.
    Wagner KD; El Maï M; Ladomery M; Belali T; Leccia N; Michiels JF; Wagner N
    Cells; 2019 Jan; 8(1):. PubMed ID: 30641926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.